Low-dose CT for MRI-free quantification of tau PET in Alzheimer's disease: a multicentre, cross-sectional, comparison study

Jan 1, 2026·
Guilherme Povala
,
Livia Amaral
,
Bruna Bellaver
,
Firoza Z. Lussier
,
Pamela C. L. Ferreira
,
Douglas Teixeira Leffa
Guilherme Bauer-Negrini
Guilherme Bauer-Negrini
,
Raphael L. de Luca e Tuma
,
Álvaro de Oliveira Franco
,
Cécile Tissot
,
Quentin Finn
,
João Pedro Ferrari-Souza
,
Eduardo R. Zimmer
,
Dana L. Tudorascu
,
Joseph C. Masdeu
,
Juan Fortea
,
David N. Soleimani-Meigooni
,
Val J. Lowe
,
Hwamee Oh
,
Brian A. Gordon
,
Belen Pascual
,
Pedro Rosa-Neto
,
Suzanne L. Baker
,
Tharick A. Pascoal
· 0 min read
DOI
Abstract
Tau PET quantification typically requires structural MRI for reference-region definition, normalisation, and segmentation, which imposes a logistical and operational burden. In this study, we evaluated whether low-dose CT can serve as a reliable MRI alternative for tau PET quantification when MRI is unavailable.
Type
Publication
The Lancet Medical Imaging & Theranostics
Status
Peer-reviewed
publications
Guilherme Bauer-Negrini
Authors
Biomedical Data Scientist
Computational neuroscientist working at the intersection of machine learning, biomedical imaging, and human genetics in neurodegenerative disease. My work applies deep learning to high-dimensional medical images, harmonizes imaging measurements across sites and acquisition protocols, and integrates imaging with genomic, proteomic, and longitudinal clinical data to characterise Alzheimer’s disease and related dementias, with particular focus on fluid and imaging biomarkers of neurodegeneration.